Health Care & Life Sciences » Biotechnology | Portola Pharmaceuticals Inc.

Portola Pharmaceuticals Inc.

Portola Pharmaceuticals Inc.
Stock Exchange Frankfurt Stock Exchange
EPS
-
Market Cap
-
Shares Outstanding
66.09 M
Public Float
56.59 M
Portola Pharmaceuticals Inc.
Stock Exchange NASDAQ Stock Market
EPS
$5.18
Market Cap
$1.8 B
Shares Outstanding
68.11 M
Public Float
63.71 M

Profile

Address
270 East Grand Avenue
South San Francisco California 94080
United States
Employees -
Website http://www.portola.com
Updated 07/08/2019
Portola Pharmaceuticals, Inc. engages in the development and commercialization of novel therapeutics in the areas of thrombosis and hematologic disorders, and inflammation. Its FDA-approved medicines include Bevyxxa (betrixaban), the oral, once-daily Factor Xa inhibitor, and Andexxa coagulation factor Xa (recombinant), inactivated-zhzo, the antidote for the Factor Xa inhibitors rivaroxaban and apixaban. The company was founded by Charles J.

Financials

View All
Created with Highcharts 5.0.14Portola Pharmaceuticals Inc.Net Income. Fiscal year is January-December. All values USD Thousands.83 35283 352137 125137 125226 505226 505269 043269 043286 090286 090350 223350 2232013201420152016201720180100k200k300k400k
Created with Highcharts 5.0.14Portola Pharmaceuticals Inc.Sales/Revenue. Fiscal year is January-December. All values USD Thousands.10 53110 5319 6259 62512 07012 07035 50435 50422 54622 54640 13040 130201320142015201620172018010k20k30k40k50k

Hollings Chase Renton
Chairman
David C. Stump
Independent Director